The French screening gap France has no national lung cancer screening program, despite strong evidence from the US NLST and Dutch-Belgian NELSON trials showing that annual low-dose CT (LDCT) screening reduces lung cancer-specific mortality by 20-26% in high-risk populations.
Pilot study rationale Foch Hospital in Suresnes launched a prospective pilot LDCT screening program from June 2023 to June 2024, recruiting through general practitioners, pharmacists, and specialists. The purpose was to demonstrate real-world feasibility and characterize findings in a French population.
Policy context The study was conducted against a backdrop of imminent national action: the French National Authority for Health (HAS), under a presidential mandate, tasked the National Cancer Institute (INCa) with implementing a national pilot program. This study directly informs that effort.
Key finding preview Of 477 enrolled high-risk participants, 1.7% had positive CT findings, and 66.7% of diagnosed cancers were in early stages (0-I), suggesting that screening with LDCT can successfully identify early-stage, potentially curable lung cancers in a French community setting.
Recruitment approach Participants were recruited through a multi-channel approach involving general practitioners, community pharmacists, and specialist physicians, reflecting a real-world population outreach strategy rather than a highly selected research cohort.
Eligibility criteria Inclusion required male or female participants aged 50-80 years who were either current smokers or former smokers who had quit within the past 15 years, with a cumulative smoking history of over 20 pack-years. These criteria align with USPSTF and emerging European recommendations.
CT imaging protocol Chest CT scans were performed using a low-dose protocol without contrast injection on a multi-slice scanner with at least 60 slices, following volumetric acquisition. The low-dose protocol minimizes radiation exposure while maintaining diagnostic image quality.
Participant demographics The 477 enrolled participants were nearly equally split: 235 males (49%) and 242 females (51%), both groups with median age 60 years. Males had slightly higher median pack-years (35 vs. 30), reflecting typical French smoking epidemiology.
Positive nodule rate Eight participants (1.7%) showed positive CT findings meeting criteria for further investigation. This rate is consistent with findings from international screening trials including NLST (positive rate approximately 1.4%) and ELCAP, validating that the French population carries comparable screening-detectable cancer burden.
Early stage distribution Critically, 66.7% of diagnosed cancers were identified at early stages (0-I), where curative surgical resection is possible and 5-year survival rates exceed 80%. This strongly contrasts with the typical clinical presentation where most lung cancers are diagnosed at stage III or IV.
Incidental non-cancer findings Beyond lung cancer, LDCT screening frequently identifies incidental findings including pulmonary emphysema, cardiovascular calcifications, and other thoracic abnormalities that may have independent clinical significance requiring follow-up.
Gender distribution of findings The near-equal male-female participation reflects the shifting French smoking epidemiology, with lung cancer burden increasingly affecting women. Female-specific screening outcomes - including potentially higher false positive rates and different histology distribution - warrant monitoring.
NLST and NELSON evidence The US National Lung Screening Trial demonstrated a 20% reduction in lung cancer-specific mortality with LDCT versus chest X-ray in high-risk smokers. The Dutch-Belgian NELSON trial confirmed a 26% mortality reduction, with the benefit being even more pronounced in women.
Pre-clinical window of opportunity Lung cancer typically spends 3-4 years in a pre-clinical detectable phase between stage IA (first visible on CT) and stage IIIA (last operably resectable). Screening exploits this window to detect cancers while they remain surgically curable.
ELCAP long-term data The International Early Lung Cancer Action Program enrolled 89,404 participants in annual LDCT screening. Among 1,257 diagnosed primary lung cancers, 81% had confirmed cancer cure after 20 years follow-up, compared to a 16% cure rate in patients diagnosed outside screening programs.
Mortality reduction estimate for France French experts estimate that organized national screening could prevent between 2,200 and 7,400 deaths per year - a substantial public health impact that creates urgency for national program implementation.
Multi-channel recruitment effectiveness Recruiting through GPs, pharmacists, and specialists enabled broad community reach, suggesting that distributed outreach rather than centralized invitation will be more effective for national program scaling in France.
Equal gender participation Achieving near-equal male-female enrollment demonstrates that both sexes can be successfully engaged in a smoking-history-based screening program. Gender parity in enrollment is important for monitoring sex-specific screening outcomes.
Low dose feasibility The absence of adverse events related to CT radiation or contrast use, combined with high image quality enabling confident nodule reporting, validates that the low-dose protocol is safe and technically sufficient for mass screening deployment.
Follow-up pathway requirements Positive screening findings require well-defined diagnostic pathways including multidisciplinary lung cancer teams, rapid access to bronchoscopy and CT-guided biopsy, thoracic surgery, and integrated oncology services - infrastructure that must be in place before national program launch.
Study size limitations With 477 participants and only 8 positive findings, the pilot provides proof-of-concept feasibility evidence but lacks statistical power for definitive conclusions about screening performance, cost-effectiveness, or false positive rates in this population.
National pilot expansion INCa's planned national pilot study will enroll substantially more participants across multiple French regions, providing the scale needed to assess performance metrics, costs, and program logistics representative of a full national program.
Long-term mortality data The pilot's follow-up period is too short to measure mortality reduction - the key outcome. Long-term follow-up of screened cohorts or randomized national pilots would provide the definitive French-specific evidence for mortality benefit.
AI integration potential As French screening scales nationally, AI-assisted CT interpretation tools could help manage radiologist workload, standardize nodule reporting using Lung-RADS criteria, and improve detection consistency across participating radiology centers.